Emtricitabine; Tenofovir Alafenamide Fumarate is Used for managing and treating HIV infection. It was first introduced by Gilead Sciences Inc in its drug Descovy on Apr 4, 2016. 3 different companies have introduced drugs containing Emtricitabine; Tenofovir Alafenamide Fumarate.

Emtricitabine; Tenofovir Alafenamide Fumarate Patents

Given below is the list of patents protecting Emtricitabine; Tenofovir Alafenamide Fumarate, along with the drug name that holds that patent and the company name owning that drug.

Filter patents by

Country : United States (US)

• Argentina (AR)
• Australia (AU)
• Brazil (BR)
• Canada (CA)
• Chile (CL)
• China (CN)
• India (IN)
• Japan (JP)
• Mexico (MX)
• Paraguay (PY)
• Philippines (PH)
• Russia (RU)
• Singapore (SG)
• South Africa (ZA)
• Thailand (TH)
• United States (US)
• Uruguay (UY)
• Eurasian Patent Organization (EA)
• World Intellectual Property Organization (WO)
• Taiwan (TW)
• European Patent Office (EP)

Patent Category : All

• All
• Combination
• Compound
• Device
• Dosage Regimen
• Formulation
• Other Forms
• Polymorph
• Process
• Use Method

Download patent list as spreadsheet

Get the complete list right in your inbox!

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Descovy	US8754065 (Pediatric)	Tenofovir alafenamide hemifumarate	Feb 15, 2033	Gilead Sciences Inc
Descovy	US9296769 (Pediatric)	Tenofovir alafenamide hemifumarate	Feb 15, 2033	Gilead Sciences Inc
Descovy	US8754065	Tenofovir alafenamide hemifumarate	Aug 15, 2032	Gilead Sciences Inc
Descovy	US9296769	Tenofovir alafenamide hemifumarate	Aug 15, 2032	Gilead Sciences Inc
Descovy	US7390791 (Pediatric)	Prodrugs of phosphonate nucleotide analogues	Jul 07, 2025 (Expired)	Gilead Sciences Inc
Descovy	US7390791	Prodrugs of phosphonate nucleotide analogues	Jan 07, 2025 (Expired)	Gilead Sciences Inc
Descovy	US7803788	Prodrugs of phosphonate nucoleotide analogues	Feb 02, 2022 (Expired)	Gilead Sciences Inc
Descovy	US6703396 (Pediatric)	Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers	Sep 09, 2021 (Expired)	Gilead Sciences Inc
Descovy	US6642245 (Pediatric)	Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane	May 04, 2021 (Expired)	Gilead Sciences Inc
Descovy	US6703396	Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers	Mar 09, 2021 (Expired)	Gilead Sciences Inc
Descovy	US6642245	Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane	Nov 04, 2020 (Expired)	Gilead Sciences Inc
Descovy	US5914331 (Pediatric)	Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane	Jan 02, 2018 (Expired)	Gilead Sciences Inc
Descovy	US5914331	Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane	Jul 02, 2017 (Expired)	Gilead Sciences Inc
Descovy	US5814639 (Pediatric)	Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds	Mar 29, 2016 (Expired)	Gilead Sciences Inc
Descovy	US5814639	Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds	Sep 29, 2015 (Expired)	Gilead Sciences Inc

Add above patents to watchlist

Emtricitabine; Tenofovir Alafenamide Fumarate's Family Patents

Unlock Global Patents

Emtricitabine; Tenofovir Alafenamide Fumarate Generic API Manufacturers

Several generic applications have been filed for Emtricitabine; Tenofovir Alafenamide Fumarate. The first generic version for Emtricitabine; Tenofovir Alafenamide Fumarate was by Apotex Inc and was approved on May 17, 2024. And the latest generic version is by Lupin Ltd and was approved on Dec 13, 2024.

Given below is the list of companies who have filed for Emtricitabine; Tenofovir Alafenamide Fumarate generic, along with the locations of their manufacturing plants worldwide.